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ABSTRACT OF DISSERTATION

BARRIERS AND FACILITORS OF HEALTHCARE USE AMONG PEOPLE WHO
INJECT DRUGS
Hepatitis C Virus (HCV) is an infection that can have grave consequences when
left untreated. Hepatitis C can be easily eradicated with direct acting antiviral therapy.
People who inject drugs (PWID) and inmates are among those with the highest incidence
of HCV. However, cure rates among this population remains low. This is, in part, related
to an interruption in the HCV care cascade such that only 30% of PWID are linked to
care and only 8% of those receive treatment. Inadequate screening and failure to be
linked to HCV care remain the largest impediments to treatment success. There is limited
research on barriers and facilitators to primary care, where screening may take place, and
linkage to HCV care among PWID. Few studies have evaluated vulnerable populations
such as those living in rural communities or inmates.
The purpose of this dissertation was to develop a broader understanding of
barriers and facilitators to healthcare utilization among PWID at the primary care and
specialist levels (linkage to care). Three manuscripts addressed important gaps in
knowledge. The first was a review of the literature to describe the state of science on
linkage to care among PWID. All but one reviewed study recruited from countries with
universal healthcare, urban areas, and opioid substitution facilities. The review of the
literature revealed that little is known about the barriers/facilitators to linkage to HCV
care faced by rural-dwelling PWID from countries without universal healthcare.
The second manuscript is a study to determine whether predictors of linkage to
care identified in urban-dwelling PWID from countries with universal healthcare
predicted seeking HCV care among PWID living in rural Appalachia. Data were obtained
from a subsample of 63 HCV positive PWID who recently used opioids, were between
the ages of 18-35 years, and lived in one of five rural counties in Kentucky. Logistic
regression revealed that recent injection drug use was the only predictor of seeking HCV
care. However, remote use of opioid substitution therapy and no transportation issues
approached clinical significance.
Although not evaluated in our second manuscript, seeing a primary care provider
(PCP) is associated with an increased likelihood of being linked to care and higher rates
of screening/diagnosis. Among rural dwelling PWID, there are subpopulations that may
face unique barriers to linkage to care. One sub-population that may be particularly

vulnerable are female PWID who are incarcerated. Therefore, the purpose of the third
study was to determine predictors of primary care use using data from 302 female
inmates from rural Appalachia with a history of injecting drugs. Age, insurance issues,
and health problems that interfere with responsibilities were predictors of PCP use.
In this dissertation, I have addressed important gaps in the literature by
determining barriers and facilitators to seeking HCV care and primary care use among
PWID from rural Kentucky. Additional studies are needed using a larger sample of rural
PWID to confirm our findings. In addition, further studies should evaluate system and
provider level barriers to linkage to care and PCP use among rural PWID.
KEYWORDS: Linkage to care, hepatitis C, primary care use, predictors, people who
inject drugs, rural
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CHAPTER 1. INTRODUCTION
1.1

An overview of hepatitis C virus
Hepatitis C virus (HCV), a blood-borne viral infection, is a national health

concern with high prevalence and incidence rates. There are approximately 2.4 million
persons living with chronic HCV in the United States (U.S.).1 In 2016, an estimated
41,200 new acute cases of hepatitis C were diagnosed.2 Injection drug use remains the
leading cause of HCV in the U.S. with an estimated 53% of people who inject drugs
(PWID) infected with HCV.3 Thus, examining ways to improve injection drug use
treatment can enhance our understanding of ways to curb the high rates of HCV in the
U.S.
Left untreated, HCV can have serious consequences including porphyria,
glomerular nephritis, cryoglobulinemia, cirrhosis, hepatocellular carcinoma, and
subsequent death.4 In 2007 alone, there were 15,106 deaths related to HCV, surpassing
deaths associated with human immunodeficiency virus (HIV) in the U.S.3,6 Up to one
fifth of persons with chronic HCV infection develop cirrhosis, making HCV the principal
reason for liver transplantation in the U.S.3,5 The morbidity and mortality rates due to
untreated chronic HCV infection are expected to climb over the next few decades,
resulting in 1.76 million persons developing cirrhosis, 1 million dying of HCV-related
complications, and 400,000 developing hepatocellular carcinoma.7An estimated 1-5% of
persons with chronic HCV will die from cirrhosis or hepatocellular carcinoma.3 HCVrelated morbidity and mortality can be prevented with prompt curative treatment, yet less
than 10% of persons with chronic HCV infections receive treatment. Therefore, it is
crucial to address barriers and optimize access to evidence-based treatments among those
with HCV infections.6, 8

1

1.2

Hepatitis C virus care cascade
The cascade of care, or care continuum, is a framework originally designed for

persons with HIV, but has been also applied to persons with HCV.8 -10 While there is no
universal consensus on defintion,8 the World Health Organization defines the HCV care
continuum as progression through screening/diagnosis, treatment, cure, to chronic posttreatment care as needed.11 At least seven stages have been identified: (1) being infected
with HCV; (2) screening for HCV antibody and being made aware of infection status; (3)
accessing specialty care; (4) receiving confirmatory HCV RNA test; (5) undergoing
fibrosis assessment; (6) being prescribed HCV treatment; and (7) achieving a sustained
virologic response (SVR) or cure.4 An eighth stage has been proposed- prevention of
reinfection in high-risk groups after being cured.12 Alternatively, the Infectious Disease
Society of America and the American Association for the Study of Liver Diseases use a
simplified framework of three major time points: screening, linkage-to-care, and
treatment uptake.13 Based on this simplified framework, screening is the process by
which at risk persons are identified and tested for HCV antibodies followed by
confirmatory testing with nucleic acid test (i.e. HCV RNA), when appropriate;13 linkageto-care is the process by which patients are evaluated by a practitioner who can manage
and treat HCV infection; and treatment uptake is the process of receiving HCV
treatment.13-14
Although PWID are at the highest risk for contracting HCV, they are the least
likely to be cured. An examination of a cross-sectional surveillance system of 2,222
PWID in Australia found that 89% had received HCV antibody testing in their lifetime of
which 57% tested positive.4 Nearly half of those who tested positive for HCV antibodies,
completed a HCV RNA test (confirmation testing).4 Of those completing testing, 76%
2

had detectable HCV RNA, but, unfortunately, only 31% were linked-to-care an HCV
specialist.4 Among those linked to care, 8% received treatment, and 3% achieved a cure.4
Hence, despite the availability of highly effective antiviral therapy, cure rates remain low
among PWID; which, in part, may be attributed to a breakdown in progression through
the HCV care cascade.
Fundamentally, appropriate screening, diagnosis (being made aware of having
HCV), and referral to a healthcare specialist are necessary for successful treatment.
Primary care providers (PCP’s), are well positioned to screen, diagnose, and refer
patients to a HCV specialist. In fact, people who follow with a PCP are nearly four times
as likely to be assessed by a HCV specialist (linked to care).15 Unfortunately, PWID
underutilize primary care services; this is more pronounced in rural communities.3, 6
Underutilization of PCP services is an important factor which compromises
proper care for PWID. Even less is known about barriers/facilitators to PCP use among
rural-dwelling PWID. Moreover, to my knowledge, there are no published reviews of the
literature or meta-analysis on linkage to HCV care among PWID. Most research on
linkage to care among PWID has been conducted in urban areas and in countries with
universal healthcare. Therefore, the purpose of this dissertation was to develop a broader
understanding of the barriers and facilitators to healthcare utilization among ruraldwelling PWID at the primary care level (screening) and at the specialist level (linkage to
care).
The subsequent chapters of this dissertation represent the foundation of my
program of research. First, a review of the literature was performed to establish the state
of science on barriers and facilitators to linkage to HCV care among PWID. In all but one

3

of the studies, participants were recruited from urban areas and in countries with
universal healthcare. Subsequently, a secondary data analysis was conducted to determine
if barriers/facilitators to seeking HCV care in rural-dwelling PWID in the US were
similar to those among urban-dwelling PWID from countries with universal healthcare.
Finally, because primary care use is a crucial first step to being screened and referred to a
HCV specialist, we conducted a secondary data analysis to determine predictors of
primary care use among rural-dwelling PWID.

1.3

Summary of subsequent chapters
Chapter Two is a review of the literature to determine barriers and facilitators

associated with linkage to HCV care among PWID. PubMed, Ovid, CINHAL,
MEDLINE, and PsychINFO were searched using the following terms: access, HCV care
continuum, HCV care cascade, barriers, facilitators, factors, injection drug use, linkageto-care, treatment evaluation, and hepatitis C. Given the limited research on this topic, no
time constraint on publication date was imposed. Twenty-three of the 134 articles
identified during the initial searches met inclusion criteria and were reviewed. Articles
were excluded if the majority of the sample was not PWID or the majority were coinfected with HIV. Seven articles met selection criteria. In all but one reviewed study,
participants were from large urban cities, in countries with universal health care, and
from addiction clinics. Little is known about factors associated with linkage to care in
rural-dwelling PWID who likely have less access to care and fewer resources.
Chapter Three is a secondary data analysis of PWID living in rural Appalachia.
The purpose of the study was to determine whether factors identified in urban
populations predicted seeking HCV care among PWID living in rural Appalachia. In the
4

parent study, data were collected using an online survey from 249 people who use drugs,
aged 18-35 years, who reported living in one of five rural counties in Appalachian
Kentucky, and using opioids in the last 30 days. We described the progression through
the HCV care cascade for the 115 participants that reported a history of injecting drugs.
Sixty-three of those PWID, reported testing positive for HCV antibodies. Logistic
regression was run using data from these 63 participants, to determine if child caregiver
status, recent injection drug use, transportation issues, homelessness, and the absence of
criminal issues were predictors of linkage to care (operationally defined as self-report of
seeking treatment for HCV).
Seeing a PCP is associated with a lower risk of infection and an increased
likelihood of being screened and linked to HCV care.15-17 Therefore, we examined
existing literature to determine what is known about barriers/facilitators of PCP use
among PWID and found that little is known about this topic. Furthermore, to our
knowledge, none of the published studies had an exclusive sample of rural dwelling or
incarcerated PWID. Therefore, Chapter Four is a secondary data analysis to determine
predictors of PCP use among incarcerated female PWID living in rural Appalachia. Data
were selected from the 302 participants who reported a history of injecting drugs from a
larger randomized control trial. Anderson’s Behavioral Model of Health Services Use
was used as a framework to identify independent predictors of PCP use from
predisposing factors, potential enabling factors, and healthcare needs. Multivariate
logistic regression analyses, using data from the 302 PWID, were used to determine
predictors of primary care use.

5

Chapter Five is a synthesis of the results from Chapters 2, 3, and 4 in reference to
how they contribute to the state of science on healthcare utilization among rural PWID.

6

CHAPTER 2. BARRIERS AND FACILIATORS TO LIKNAGE TO CARE: A REVIEW
OF THE LITERATURE
Abstract
BACKGROUND: Hepatitis C virus (HCV), a blood-borne viral infection,
disproportionately affects people who inject drugs (PWID). However, PWID are the least
likely to receive HCV treatment due to difficulty navigating the HCV care continuum.
PURPOSE: Conduct a review of literature to describe the state of science on barriers and
facilitators associated with linkage-to-care among PWID. METHOD: PubMed, Ovid,
CINHAL, MEDLINE and PsychINFO searches using the following terms: HCV care
continuum, HCV care cascade, barriers, facilitators, factors, injection drug use, linkageto-care, and hepatitis C. RESULTS: Seven articles met selection criteria. Barriers to
linkage-to-care at the patient-level included ongoing substance use, limited knowledge or
understanding to make an informed decision, competing priorities, and symptoms.
Provider-level facilitators included clinical manifestations (i.e. elevated liver enzymes
and diagnosis of cirrhosis) and a trusting patient-provider relationship. Distance traveled,
lack of transportation, forgetting appointments, and early appointment times were
system-level barriers to linkage-to-care. Barriers and facilitators are most frequently
assessed in urban-dwelling PWID. Little is known about barriers faced by their rural
counterparts. DISCUSSION: Future research should be dedicated to exploring the
barriers and facilitators faced by rural-dwelling PWID from countries without universal
healthcare.

2.1

Introduction
Hepatitis C virus (HCV) disproportionately affects persons who inject drugs

(PWID) with an estimated 30% of PWID between 18-30 years old infected with chronic
HCV.1 HCV infection can easily be eradicated with treatment success rates approaching
100%.2 In spite of advancements in antiviral therapy, the percentage of PWID who are
cured remains low.3,4
Successful treatment requires progression through a three step HCV care cascade:
(1) screening, (2) linkage-to-care and (3) treatment uptake.4 Screening is the process of
testing at risk persons for HCV antibodies and nucleic acid test (when appropriate) and
then making him/her aware of their status.4 Linkage-to-care is the process of being
evaluated by a HCV specialist and treatment uptake is the process of taking prescribed
treatment.4 However, successful treatment is rarely achieved, as most people are lost
along the care cascade. In a large cross-sectional study of PWID, an estimated 31% of
those with an active infection were linked to care, 8% were treated, and 3% were cured.3
The largest dropout occurred between diagnosis and linkage-to-care with a nearly 70%
attrition rate occurring after screening and diagnosis.3
PWID are disproportionately burdened with complex social, medical, and
psychiatric co-morbidities that generate difficulties navigating the HCV care continuum.5
A better understanding of factors that affect linkage to care is needed to improve cure
rates. Therefore, the purpose of this review was to describe the state of the science
regarding barriers and facilitators to linkage to HCV care among PWID.

8

2.2

Methods
2.2.1 Search Strategy and Selection Criteria
PubMed, Ovid, CINHAL, MEDLINE and PsychINFO databases were searched

using a combination of the following search terms: access, HCV care continuum, HCV
care cascade, barriers, facilitators, factors, injection drug use, linkage-to-care, treatment
evaluation, and hepatitis C. No time constraint was enforced given the limited available
literature. Article reference lists were examined for additional relevant studies. Articles
were included if they were from peer-review journal articles, published in English, and
examined barriers/facilitators to linkage-to-care. Articles were excluded if less than half
of the sample were not injection drug users and if all participants were co-infected with
human immunodeficiency virus (HIV).
The initial search yielded 134 articles. The titles of all 134 articles were reviewed
for relevance. A total of 106 articles were either duplicates or did not evaluate linkage-tocare. The abstracts of the remaining 28 were reviewed. Five additional studies were
eliminated because they did not include barriers/facilitators to linkage-to-care. Among
the remaining 23 articles, 17 were eliminated because the majority of the population did
not have a history of injection drug use, or the sample was almost exclusively co-infected
with HIV. Six articles met inclusion and exclusion criteria. Review of reference lists
yielded one additional study. No meta-analyses on linkage to HCV care among PWID

2.2.2 Data Extraction
Components of the study of interest were extracted and organized in a chart (see
Table 1). Barriers and facilitators were categorized according to three levels- patient,
provider and healthcare system. Patient-level barriers are related to patient characteristics
9

such as race, education or socioeconomic status. Provider-level barriers included a
healthcare provider’s knowledge, bedside manner or experience with a specific
population and/or condition. System-level barriers are those that occur because of the
infrastructure or design of the healthcare system. For example, the distance between
one’s home and the nearest doctor’s office. Some barriers and facilitators could be
conceived as fitting multiple levels. In these cases, the level was determine based on a
consensus among authors.
Barriers and facilitators were further grouped under themes. At the patient level
they were grouped under: drug use, patient symptoms, HCV knowledge, fear, and social
factors. At the provider level they were grouped under: clinical findings and patientprovider relationship. At the system-level, barriers and facilitators were grouped together
as there were not enough variations to develop themes. Variables that were not predictors
of linkage-to-care were not included in the results.
2.2.3 Quality Assessment
Quantitative studies were assessed for bias using the Scottish Intercollegiate
Guidelines Network (SIGN) (Table 2).6 The SIGN is used to rank the quality of studies
as high, acceptable or low using a 10-item checklist with the following domains: subject
selection, methodology, confounding variables, and statistical analysis.6 SIGN is
recommended for critiquing cohort studies.6 Qualitative studies were assessed for bias
using the Critical Appraisal Skills Programme (CASP) Check List (Table 3).7 The CASP
is a 10 question check list that evaluates the rigor of methodology, validity of the results,
and the value of the study findings on the local community.7 There are no scoring
systems for the SIGN or CASP.6-7 All seven articles were assessed by two independent
10

readers and disagreement was resolved with a third reader. Overall, bias was relatively
low (Tables 2 and 3).

2.3

Results
Two studies were qualitative,8-9 four were quantitative (two cross-sectional and

two cohort studies) 10-13 and one was mixed methods.13 Four studies were conducted in
Australia,8,10-11, 14 two in Ireland 9, 13 and one in Greece.12 In all seven studies, patients
were recruited from addiction-based clinics or community service facilities. Only two
studies were conducted after direct acting antiviral therapy became standard of care.12, 13
2.3.1 Patient Level
2.3.1.1 Drug Use
On-going and recent drug use emerged as a barrier to linkage-to-care in four of
the seven reviewed articles.9-10, 13, 14 Continued substance abuse including injection drug
use and alcohol use were associated with poor attendance to consultation with a HCV
specialist.13, 9 In a cross-sectional study, participants who were receiving Opioid
Substitution Treatment (OST) or reported injecting drugs in the last 6 months were less
likely to report having been evaluated by a HCV specialist.14 Conversely, persons who
had not injected drugs in the last six months were more likely to attend specialty
consultation.10 None of the authors suggested reasons for why ongoing drug use was a
barrier. Potential reasons could include lack of referral, which is a provider-level barrier
or persons who have recent or ongoing drug use may not be willing/able to prioritize
HCV treatment, which is a patient-level barrier. Persons with recent drug use may also

11

believe that they must be sober for a specified amount of time prior to being treatment
eligible and, therefore, do not attend their consultation visit—also a patient-level barrier.
2.3.1.2 Lack of Symptoms
HCV infection is often asymptomatic. Being asymptomatic or the perception of
being physically well, is associated with low rates of engagement with treatment services.
8-9, 11

Participants in a qualitative study reported that being asymptomatic or feeling well

was a reason for not seeking care while a decline in physical health or presence of
symptoms attributed to HCV was a motivator for seeking care.9 In contrast, participants
with HCV-related symptoms were more likely to have seen a HCV specialist.11 While it
was not possible to determine if this was attributed to provider referral or an individual
seeking treatment, it is clear that the presence or absence of symptoms was an important
factor in treatment engagement.
2.3.1.3 HCV Knowledge
HCV-related knowledge was noted to be a facilitator in three of the seven
articles.8-9, 14 Greater HCV knowledge (transmission, treatment options) and an
understanding of the potential severity of untreated HCV were associated with a higher
likelihood of being linked-to-care.8-9, 14 In contrast, a lack of knowledge about the
diagnosis, the required workup, and treatment options emerged as barriers to seeking
care.9
2.3.1.4 Fear
Fear also served as both a patient-level barrier and facilitator. Specifically, fears
regarding side-effects of treatment, having a liver biopsy, the inefficacy of treatment, and
12

self-injecting PEGylated Interferon were barriers.8-9, 13 Surprisingly, one of these studies13
was conducted after DAA therapy which is known for fewer side effects. In addition,
persons who reported hearing positive accounts from those who received HCV treatment
(and therefore had less fear) were more likely to receive HCV care.8-9 Persons who
witnessed friends become ill, require liver transplant or die related to HCV were more
likely to be engaged in specialty care.8-9 Thus, patients’ specific fears can either increase
or decrease the likelihood of seeing a HCV specialist.
2.3.1.5 Social Factors
Social factors were identified as barriers to linkage-to-care in four of the studies.89, 11, 13

In an observational cohort study in which participants were asked to complete a

six-item questionnaire on social functioning (financial problems, conflict with partner,
spouse, relatives or employer, and living with drug users), lower social functioning scores
were associated with lower likelihood of attending scheduled consultation with a HCV
specialist.11 Additional competing identified social factors included pending court cases
(i.e. custodial sentencing), employment obligations, poor financial status, and
responsibilities for children.8-9, 11, 13 PWID have complex social circumstances which
influence their ability to be linked to care.
2.3.2 Provider Level
Provider-level barriers and facilitators to linkage-to-care were addressed in less
than half of the reviewed studies. Two major themes were identified as important: clinical
findings and provider-patient relationships.
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2.3.2.1 Clinical Findings
Clinical findings included findings from laboratory values or diagnostic imaging.
In the reviewed studies, participants with elevated liver enzymes or a prior diagnosis of
cirrhosis were more likely to attend initial consultation appointment as compared to
participants without such complications.10, 14 However, it cannot be ascertained if these
persons were more likely to be referred to a specialist by a provider based on their
findings/assessment or if the patients were more likely to attend referral since they were
aware of this information.
2.3.2.2 Patient-provider Relationship
In a qualitative study, participants were asked to identify factors that facilitate or
inhibit linkage-to-care.9 Participants emphasized the importance of having continuity of
care. 9 Seeing the same provider created a comfortable environment which in turn
supported their engagement in care. 9 Another important facilitator was believing that the
provider was genuinely concerned about their well-being. 9 Participants also identified
having trust and confidence in their provider as an important influential factor. 9
Specifically, participants needed to be confident that their provider had adequate
knowledge about hepatitis C. 9 Conversely, participants who felt that their provider was
impersonal or distant, were less likely to engage in HCV care. 9 Lastly, participants
reported feeling stigmatized as a barrier to seeking care. 9 If the participant felt that their
drug use caused inequitable treatment by their provider, they were less likely to seek
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HCV care.9 Verbal and non-verbal communication from providers has the ability to
facilitate or impede linkage-to-care.
2.3.3 System Level
System-level barriers/facilitators to linkage-to-care were identified in three
studies.9, 12-13 In a qualitative study, participants identified forgetting appointment
dates/times which they attributed to the length of time between making the appointment
and the actual appointment date, and a lack of appointment reminders as barriers to
attending consultation appointment.9 Other barriers included lack of transportation, long
distance to nearest HCV specialist, and appointment times early in the day.12-13

2.4

State of the Science
There are several limitations with the reviewed literature and gaps in the

knowledge. First, there is an overall lack of knowledge about barriers and facilitators of
linkage to care among PWID with HCV. There were only seven studies that met
inclusion criteria with nearly 40% being qualitative data. Most of the quantitative studies
were cross-sectional. Only one study examined longitudinal data over 2-5 years.10
Barriers to linkage to care at one time point may not predict linkage to care over the years
to come; barriers and facilitators may evolve over time. Moreover, provider- and systemlevel barriers were only reported in three articles. It is unlikely that all provider- and
system-level barriers have been identified.
The results of these studies have limited generalizability as the majority (all but
one) 8 recruited participants from urban cities, countries with universal healthcare, and
community health centers, needle exchange programs or from addiction treatment
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facilities. These participants likely have better access to resources and system-level
engagement than PWID who reside in rural areas, countries with a multi-payer healthcare
system, and third-world countries, or are not engaged in addiction treatment. Predictors
of being evaluated by PCP for HCV among rural-dwelling PWID were reported in only
study in the United States.11 These findings suggest similarities in predictors of seeing a
PCP for hepatitis C infection as urban populations.11 However, further research is needed
to confirm the generalizability of such findings to rural populations.
The recruitment sites for three studies employed staff with the intent of increasing
engagement in HCV specific services.10-11, 13 In one study specifically, all participants
who failed to attend their specialty appointment were given another appointment and
offered additional support aimed at increasing linkage to care.10 Participants in the other
two studies were recruited from facilities that offered on-site hepatitis C treatment
facilities. 11, 13 This is not standard of practice in most clinics in the U.S., which also limits
generalizability.
Barriers related to fear of side effects treatment and knowledge may be less
relevant. Only two studies were conducted after direct-acting antiviral (DAA) therapy
became standard of care.12, 13 Interferon-based therapy was notorious for debilitating sideeffects and low cure rates whereas DAA therapy is known for fewer side effects and
higher efficacy.2 It is likely that fear of side effects, concerns about efficacy, and being
aware of others negative treatment experiences are less significant today. Likewise, DAA
therapy has been widely advertised, which provided public education about treatment and
HCV. Therefore, a lack of knowledge about treatment availability may also be less
significant. However, to our knowledge this has not been formerly evaluated.
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Lastly, linkage to care was operationally defined differently in each study.
Definitions ranged from objective measures such as documented referral and attendance
to specialist consultation10-11 or engagement in treatment services13 to self-report
measures such as “have you ever gone to see a specialist about your HCV?”9 Refer to
Table 1 for more details. This variation could explain differences in the
barriers/facilitators found in each study and limits comparisons across studies.

2.5

Conclusion
Little is known about the barriers and facilitators to linkage to care among PWID.

In particular with respect to vulnerable populations such as those living in rural
environments and in countries without universal healthcare. Future research should focus
on filling the above identified gaps in knowledge and advancing the state of the science.
Specifically, longitudinal data that focuses on vulnerable populations with high rates of
infections such as those residing in rural areas and former/current inmates. Ideally, a
large observational study should be conducted following rural PWID that test positive for
HCV antibodies in their natural environment (not recruited only from addiction clinics or
community resource facilities) over several years to determine predictors of linkage to
care. In addition, future research should focus on provider- and system-level barriers as
this is likely more pronounced in rural communities. More current research is also needed
in the new DAA treatment era to determine if fear of side effects or the ineffectiveness of
treatment is still relevant. Lastly, future studies should attempt to obtain more objective
predictor variables as opposed to relying on self-report measures and consistency should
be used in how linkage to care is defined. In the interim, caution should be used in
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generalizing these findings to rural-dwelling PWID from countries without universal
healthcare.
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Table 2.1 Barriers and Facilitators to Linkage to Hepatitis C Care among People Who
Inject Drugs
Author
Design
Location
Sample
Linkage-toBarriers and
(Date)
(Facility,
Care
Facilitators
Country)
Operational
Definition
Fortier, E.
(2015)

Observational
cohort

Islam, M.
(2012)

Prospective
Cohort

Treloar, C.
(2013)

Qualitative

Nine clinics:
four OST, two
private OST
clinics, two
community
health centers
and one
Aboriginal
communitycontrolled health
organization
Australia
Redfern Harm
Minimization
Clinic- a needle
syringe program
Australia
Three OST
clinics (inner
city private
clinic, outer
metropolitan
public clinic and
regional city
public clinic)
and one
community
center within a
large rural town;
Onsight HCV
clinic

415
former/current
injection drug
users

Referred to a
specialist and
attended their
appointment

Barriers:
1. Lower social
functioning (six-item
questionnaire: money
problems, conflict with
partner/spouse, relatives
or employer, living with
people who use)

212 injection
drug users
classified as > 6
months or < 6
months

Uptake of
referral/attended
appointment

Facilitators:
1. Elevated liver enzymes
2. No recent injection
drug use

57 clients with
history of
injection drug
use

Engaged with
treatment services

Barriers:
1. Perception that they
were physically well/had
no symptoms related to
HCV
2. Concern about side
effects and efficacy of
treatment
3. Competing Priorities:
pending court cases,
interference with
employment
4. Fear of sharing of
information between HCV
clinic and OST clinic
Facilitators:
1. Witnessing friends
becoming ill, requiring
liver transplant or dying
related to HCV.
2. Positive accounts from
others who sought
treatment-related services
3. Awareness of HCV
potential severity

Australia
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Table 2.1 (Continued)
Swan, D.
(2010)

Qualitative

Two addiction
clinics, a
community dropin center, a
general practice,
two hepatology
clinics, and an
infectious
disease clinic

36 current and
former injection
drug users

Not defined

101 with history
of injection drug
use

Access to HCV care

634 substance
abusers, mix of
injection (83%)
and noninjection (17%)

“Have you ever
gone to see a
specialist about your
hepatitis C?”

68 former
injection drug
users

Barriers to
attendance of initial
HCV clinic
appointment

Ireland

Souliotis, K.
(2017)

Cross-sectional
study

Grebely, J.
(2011)

Cross-sectional
study

Primary services,
health vans,
community
services, daycare centers
Greece
Hepatitis C
Council and
Hemophilia
Foundation
Australia mailing
lists, from OST
clinics,
pharmacies that
dispense
methadone and
needle and
syringe programs
Australia

Crowley, D.
(2017)

Cross-sectional/
Mixed-method

OST facility
Ireland

HCV = Hepatitis C Virus; OST = Opioid Substitution Treatment
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Barriers:
1. Employment
obligations
2. Lack of HCV education
investigations, treatment
3. Continued substance
use
4. Lack of remindersforgot appointments
5. Lack of opportunity
6. Fear of liver biopsy,
self-injection
9. Concerns about side
effects
10. Ineffective treatment
options
11. Responsibility of
children
Facilitators:
1.Good relationships with
health care providers
2. Awareness of potential
health implications
3. Seeing others visibly ill
or dying due to HCV
4. Presence of symptoms
5. Seeing peers/family
complete treatment
Barriers:
1. Financial burden of
health services
2. Deteriorated health
status
3. Lack of transportation
Barriers:
1. Recent injection drug
use (< 6 months).
2. HCV-related/ attributed
symptoms
3. Cirrhosis
4. Receiving opiate
therapy
Facilitators:
1. Greater HCV
knowledge
2. Previously diagnosed
with cirrhosis
3. Greater HCV symptoms
score
4. Not receiving OST
Barriers:
1.On-going drug and
alcohol use
2. On-going injecting drug
use
3. Custodial sentencing
4. Fear around invasive
HCV treatment and
interventions
5. Attendance to early
appointments
6. Lengthy distance from
clinic
7. Chaotic personal and
family lifestyles/family
responsibilities.

Table 2.2: Scottish Intercollegiate Guidelines Network Cohort Check List
Fortier
Islam
Souliotis

Grebely

The study addresses an appropriate
and clearly focused question.

Yes

Yes

Yes

Yes

The two groups being studied are
selected from source populations that
are comparable in all respects other
than the factor under investigation.

Yes

Yes

Yes

Yes

The study indicates how many of the
people asked to take part did so in
each of the groups being studied.

No

No

Yes

Yes

The likelihood that some eligible
subjects might have the outcome at
the time of enrolment is assessed and
taken into account in the analysis.

N/A

N/A

N/A

N/A

What percentage of individuals or
clusters recruited into each arm of the
study dropped out before the study
was completed?

Unable to
determine

Unable to
determine

Unable to
determine

Unable to
determine

Comparison is made between full
participants and those lost to follow
up, by exposure status.

No

No

No

No

The outcomes are clearly defined.

Yes

Yes

Yes

Yes

The assessment of outcome is made
blind to exposure status. (If the study
is retrospective this may not be
applicable).

Unable to
determine

N/A

N/A

Unable to
determine

Where blinding was not possible,
there is some recognition that
knowledge of exposure status could
have influenced the assessment of
outcome.

N/A

N/A

N/A

N/A
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Table 2.2 (Continued)
The method of assessment of
exposure is reliable.

Yes

Yes

Yes

Yes

Evidence from other sources is used
to demonstrate that the method of
outcome assessment is valid and
reliable.

No

No

Yes

No

Exposure level or prognostic factor is
assessed more than once.

No

No

No

No

The main potential confounders are
identified and taken into account in
the design and analysis.

Unable to
determine

Unable to
determine

No

Unable to
determine

Have confidence intervals been
provided?

Yes

Yes

No

Yes

How well was the study done to
minimize the risk of bias or
confounding?

Acceptable Acceptable Acceptable Acceptable

Taking into account clinical
Yes
considerations, your evaluation of the
methodology used, and the statistical
power of the study, do you think there
is clear evidence of an association
between exposure and outcome?

Yes
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Yes

Yes

Table 2.3 Critical Appraisal Skills Programme Check List
Treloar
Swan

Crowley

Was there a clear
statement of aims of
the research?

Yes

Yes

Yes

Is a qualitative
methodology
appropriate?

Yes

Yes

Yes

Was the research
design appropriate to
address the aims of
the research?

Yes

Yes

Yes

Was the recruitment
strategy appropriate to
the aims of the
research?

Yes

Yes

Yes

Was the data collected
in a way that
addressed the research
issue?

Yes

Yes

Yes

Has the relationship
between researcher
and participants been
adequately
considered?

No

No

Yes

Have ethical issues
been taken into
consideration?

Yes

Yes

Yes

Was the data analysis
sufficiently rigorous?

Yes

Yes

No

Is there a clear
statement of findings?

Yes

Yes

No

How valuable is the
research?

Very valuable

Very valuable

Valuable
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Figure 2.1 Progression Through the Hepatitis C Care Cascade
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testing
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medication and
duration
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• Treatment prescribed
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Prevention of
Reinfection
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CHAPTER 3. PREDICTORS OF SEEKING HEPATITIS C CARE AMONG PEOPLE
WHO INJECT DRUGS LIVING IN RURAL KENTUCKY
Abstract
Background: An estimated 3% of persons who inject drugs (PWID) with hepatitis
C virus (HCV) will progress through the care cascade and be cured. This is due, in part,
to challenges in being linked to HCV care. Several barriers to linkage to HCV care
among PWID have been identified, but there are limited studies in rural inhabitants.
Purpose: To determine whether the factors associated with linkage to care in urban areas
predict seeking HCV care among PWID with HCV in rural Kentucky. Methods: Data
were collected through an online survey of 115 PWID between 18-35 years old living in
one of five rural counties. Logistic regression was used to identify predictors of seeking
HCV care. Results: A majority (83%) reported being screened for HCV of which
approximately 66% reported testing positive. Of those testing positive, 60% reported
seeking treatment, 8% reported receiving treatment, and 3% reported being cured. The
PWID with self-reported HCV (n=63) in our sample were predominately Caucasian
(98%) and male (62%). Participants who did not self-report recent injection drug were
88% less likely to have sought HCV care (OR 0.12, p = 0.049). Recent opioid
substitution therapy and transportation issues were important but non-significant factors
(OR 5.002, p = 0.097; OR 3.169, p = 0.089, respectively); recent criminal history,
homelessness, and being a caregiver were not predictors. Conclusion: The number of
PWID who progressed through HCV care cascade was similar to other studies. Remote
drug use placed people at an increased risk for not seeking HCV care. Additional
research is needed to confirm these findings due to the small sample size.
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3.1

Introduction
Hepatitis C virus (HCV) disproportionately affects persons who inject drugs

(PWID) with an estimated 30% of PWID between 18-30 years old infected with chronic
HCV.1 HCV infection can easily be eradicated with treatment success rates approaching
100%.2 In spite of advancements in antiviral therapy, the percentage of PWID who are
cured remains low.3,4 Thus, it is crucial to enhance engagement in healthcare services
among PWID.
Successful treatment requires progression through a three step HCV care cascade:
(1) screening, (2) linkage-to-care and (3) treatment uptake.4 Screening is the process
whereby persons are tested for HCV antibodies and nucleic acid test (when appropriate)
and made aware of his/her status.4 Linkage-to-care is the process by which people with
HCV are evaluated by a practitioner experienced in the management and treatment of
HCV (i.e. a hepatitis C specialist).4 Treatment uptake is the process of receiving
treatment.4 However, successful treatment is rarely achieved, as most people are lost
along the cascade of care. For example, in a large cross-sectional study of PWID, 89%
were screened at least once in their lifetime with over half (57%) testing positive.3 An
estimated 31% of those with an active infection were linked to care, 8% received
treatment, and 3% were cured.3 The largest dropout occurred between diagnosis and
linkage-to-care with a nearly 30% attrition rate occurring after diagnosis.3 Hence, it is
essential to examine barriers to receiving treatment among PWID.
Several barriers to linkage to HCV care have been identified at the patient level
including on-going/recent drug use, being asymptomatic, and poor HCV knowledge. As
an example, on-going or recent drug use is an important hindrance to being linked to
HCV care.5-7, 11 Participants who reported receiving Opioid Substitution Treatment (OST)
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or injecting drugs in the last 6 months were less likely to report being evaluated by a
HCV specialist.5 In contrast, participants who had not injected drugs in the last six
months were more likely to be linked to care. 6-7, 11 Moreover, being asymptomatic can
also be a barrier to linkage-to-care. Participants in a qualitative study reported not having
symptoms or feeling well as reasons for not seeking care.7 Others reported seeking HCV
care when they experienced a decline in their physical health or developed symptoms,
which they attributed to HCV.7 In addition, Hepatitis C virus knowledge can be a
facilitator to HCV care. Patients who understand the potential severe consequences of
remaining untreated are more likely to seek care.7-8 In contrast, a lack of knowledge about
the diagnosis, the required workup, where to get treatment, and treatment availability can
be deterrents to seeking care.7
Moreover, additional patient barriers include fears and social circumstances. In
previous studies, fear of treatment-related side-effects, liver biopsy, perceived low
treatment efficacy, and/or having to self-inject medications were reported as barriers.7-8 In
contrast, fear may serve as a motivator such that patients who witness friends becoming
ill, requiring liver transplants or dying from HCV, report seeking HCV care.7,8
Additionally, several social circumstances may pose significant barriers to HCV care
among PWID. In an observational cohort study, participants were asked to complete a
six-item questionnaire on social functioning (financial problems, conflict with partner,
spouse, relatives or employer, and living with drug users).12 Lower social functioning
scores were associated with lower likelihood of attending a scheduled consultation with
HCV specialist.12 Other identified competing priorities included legal issues (i.e.
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custodial sentencing), employment obligations, family responsibilities, poor financial
status, and chaotic lifestyles.10-11
In addition to patient-level barriers, several system-level barriers exist in the
literature. Participants in a qualitative study identified forgetting appointment dates/times,
which they attributed to the extended length of time between making the appointment and
the appointment date compounded by the lack of appointment reminders as barriers to
attending their consultation appointment.7 Other barriers were lack of transportation,
distance to nearest HCV specialist, and appointment times early in the day.10-11 It is
important to examine such system level barriers to understand ways to mitigate their
detrimental impact on HCV care among PWID.
Clinical findings and provider-patient relationships are important facilitators to
linkage to care. Elevated liver enzymes and/or a prior diagnosis of cirrhosis were
associated with higher likelihood of attending initial consultation appointment.5,6 In a
qualitative study, continuity of care, believing the provider was genuinely concerned
about their well-being, and having trust and confidence in their provider were identified
as important facilitators.7 Participants who felt that their provider was distant or felt
stigmatized were less likely to seek care.7 Interactions with and responses of providers
can have a meaningful impact on linkage-to-care.

3.2

Purpose and Specific Aims
Given the challenges that exist in enhancing care for PWID with HCV, it is

important to further explore ways to improve their access to care. The majority of
existing studies were conducted in urban areas and in countries with universal healthcare
and/or from opioid substitution facilities. However, less is known about the barriers and
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facilitators to linkage to HCV care among PWID who live in rural areas without universal
healthcare where health disparities are greater. Thus, the purpose of this study was to
describe progression through HCV care cascade and determine barriers and predictors of
linkage to HCV care among rural PWID. The specific aims were to (1) determine
differences in sociodemographic variables between those who did or did not seek HCV
care; (2) describe progression through the HCV care cascade; (3) describe self-reported
reasons for not seeking HCV care; and (4) determine which factors associated with
linkage to HCV care in urban areas predict seeking HCV care in rural residents who
inject drugs.

3.3

Methods
3.3.1 Sample and Setting
The present study was a secondary analysis of data from a study to determine the

utility of an online survey (about substance misuse and related risk behaviors) to screen
and enroll a rural community of people who use drugs (PWUD). Initial participants were
recruited via advertisements at community cookouts, use of flyers, and local study staff
from outreach facilities. Additional PWUD were recruited using respondent-driving
sampling. All participants were required to complete an online screening survey to
confirm eligibility. Inclusion criteria were: self-reported use of opioids (prescription
opioids, heroin, buprenorphine, methadone, and synthetic opioids) in the last thirty days
to get high; living in one of five rural counties in Appalachia Kentucky; and between 1835 years of age. Eligibility was confirmed using date of birth to determine age and an
online screening tool to assess opioid use and local community knowledge, respectively.

29

A total of 249 participants met inclusion criteria and were enrolled between August 2017
to July 2018. Among the 115 PWID participants who reported a prior history of injection
drug use, 63 reported screening positive for HCV in their lifetime and were included in
the data analysis (Figure 1).
3.3.2 Measures
3.3.2.1 Sought HCV Care
The primary outcome was linkage to HCV care defined as the process of being
evaluated by a practitioner experienced in the management and treatment of HCV (i.e. a
hepatitis C specialist).4 For this study, we operationally defined linkage-to-care as
responding ‘yes’ to the question: “have you ever sought treatment for your hepatitis C
infection?”
3.3.2.2 Predictor Variables
Predictor variables chosen based on literature review were: (1) child caregiver
status: “Are you the primary caregiver for any children” (yes); (2) recent injection drug
use: “I have not injected in the past 6 months” (yes); (3) transportation issues: “In the past
6 months, have you been unable to do something that you needed to do because you did
not have a way to get there?” (yes) (4) homelessness: “In the past 6 months, have you
been homeless at any time?” defined as living on the street, or in a car, park, abandoned
building, or shelter; (yes) and (5) criminal issues: “Check all that apply: in the past six
months have you been in jail, prison, probation, parole, had a warrant out for your arrest
or none of the above” (at least one checked).
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3.3.3 Ethics
Institutional Review Board approval was obtained at both study sites. All data
were protected by a Federal Certificate of Confidentiality. Participants were provided the
links to the screening survey, informed consent, and the main survey were posted on the
study’s website hosted by WordPress. Those who completed the screening survey and
met inclusion criteria, were directed to sign the informed consent prior to completing the
survey. De-identified data were kept in a safe location.
3.3.4 Procedures
Those who met inclusion/exclusion criteria were asked to complete the online
survey that assessed rural risk environments; drug use patterns; human immunodeficiency
virus (HIV) and HCV risks; the risk and occurrence of overdose; and use of at-home HIV
testing. In addition to the standard survey questions, the participants who reported not
seeking HCV care were asked to select (all that apply) from a list of predetermined
reasons and/or fill-in-the-blank for additional reasons they had not sought care.
3.3.5 Data Analyses
Data were analyzed using SPSS Statistics 25. Specific Aim 1 was addressed by
between groups comparisons using Chi Square. Descriptive statistics were calculated
(means and standard deviations or frequency and percentages depending on level of
measurement) to address Specific Aims 2 and 3. Univariate logistic regression were
conducted to address Specific Aim 4 in which the following independent variables were
entered in one step: (1) child caregiver status (2) recent injection drug use (3)
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transportation issues (4) homelessness and (5) criminal issues. There was no
multicollinearity identified among variables. Alpha was set a priori at 0.05

3.4

Results
3.4.1 Sample Characteristics
The majority of the 63 HCV positive participants were Caucasian (98.4%), male

(63.5%), and unemployed (66.7%). Almost 42% reported their highest level of education
as a high school diploma or General Education Development (GED). There were no
significant differences in gender, race, education, or employment status between
participants who reported seeking HCV care and those who did not seek care.
3.4.2 Progression through the HCV Care Cascade
A total of 115 participants reported a lifetime history of injection drug use. As
depicted in Figure 1, 83% of PWID reported being screened for HCV in their lifetime. Of
those, 65% reported testing positive with 60% of those reporting seeking HCV care.
However, only 8% of those who sought care reported receiving treatment and only 3%
were cured.
3.4.3 Self-Reported Barriers to Not Seeking Care
Self-reported barriers are listed in Table 2. The most frequently selected barrier
was could not afford care (25%) followed closely by not knowing where to go (22.2%)
and not having insurance coverage (19.44%). Other barriers in decreasing order of
frequency were not worried about HCV (13.89%), did not know treatment was available
(11.11%), transportation problems (8.33%), and being worried about treatment side
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effects (5.56%). Ten participants provided self-generated barriers as follows: recent or
ongoing drug use (11.11%), worried the doctor would not treat them (5.56%), being
incarcerated (2.78%), being worried about side effects (2.78%), being worried it would
be a waste of time (2.78%), and being recently diagnosed (2.78%). These reasons were
not included in our analysis, as we did not have corresponding data for those who sought
HCV care.
3.4.4 Predictors of Seeking Hepatitis C Care
People who self-reported they did not inject drugs in the last six months were
88% less likely to report seeking HCV care (OR 0.12, 95% CI 0.015-0.994, p=0.049).
Self-reported use of Opioid Substitution Therapy (i.e. methadone or Suboxone) in the last
six months and not being able to do something in the last six months due to not having
transportation (transportation issues) approached statistical significance (OR 5.002,
0.748-33.446, p = 0.097; OR 3.169, 0.839-11.974, p = 0.089, respectively). Self-report of
criminal issues, homelessness, and being the primary caregiver of a child in the last six
months were not significant predictors of seeking HCV care.

3.5

Discussion
Progression through the HCV care cascade in our study was similar to the

findings of an Australian study in which a comparable percentage of PWID were
screened for HCV in their lifetime.3 However, only half as many PWID with HCV in
their sample were linked to HCV care compared to our study. This is surprising because
in contrast to the U.S., Australia has universal healthcare. We expected that fewer
participants would be linked to care in the U.S because of costs associated with a
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multiplayer healthcare system. It is possible that the difference between studies may be
based on how we operationally defined linkage to care (have you ever sought treatment
for HCV). In the Australian study, linkage to care was objectively measured as
attendance to an HCV specialist. In contrast, we measured linkage to care as self-report
of seeking care and therefore our findings are more vulnerable to self-report bias.
Alternatively, our participants may have understood ‘sought treatment for HCV’ to mean
seeing their PCP rather than seeing a HCV specialist. Despite differences in linkage to
care rates in our study and the Australian study, there was a similarly low percentage of
participants who received treatment and were cured. This suggests that a greater
percentage of those linked to care in rural US did not receive treatment. This could be
due to a difference in treatment eligibility between Australia and our sample or it could
be that our sample faces more barriers to treatment uptake.
Inconsistent with results from urban-dwelling populations,5-6, 11 recent injection
drug use was a predictor of being linked to care. Our findings are interesting. Even
though only six participants reported recent injection drug use, recent injection drug use
predicted seeking HCV care. One reason for this difference could be the wording of the
question; participants were asked to select all that apply with no recent injection drug use
defined as, “I have not injected drugs in the last 6 months.” Perhaps they were confused
by this statement. Moreover, perhaps our study differs from the total rural-dwelling
PWID population in that they have better resources which allow them to be linked to care
despite recent drug use. Using Suboxone or methadone therapy have also been identified
as a barrier to linkage to care in prior studies5-6 and approached significance in our study.
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This difference may be due to our smaller sample size. Future studies with more robust
samples should further explore this relationship.
Consistent with our predictions and similar to a prior study,7 a large portion of
participants in our study reported not knowing there was treatment for HCV and/or not
knowing where to get treatment as barriers to seeking care. This is not surprising as
PWID residing in rural Kentucky may often need to cross county lines to receive HCVspecialty care. This further illustrates the importance of providing education about
treatment availability/accessibility to all PWID.
Fear of side-effects was commonly reported as a barrier in prior studies.7-8 One
reason it was not common in our study may be related to the time of data collection. In
prior studies, data were collected when PEGylated interferon (well-known for its severe
side effects) was frequently used, while our data were collected in the era of direct acting
antiviral therapy, which has fewer side effects.
Not surprisingly, social circumstances such as legal issues, homelessness, and
family responsibilities have been reported as barriers to linkage to care elsewhere.10-12
One possible reason why our findings differed is that our sample size was rather small. It
could also be that other non-measured social circumstances have a greater influence on
linkage-to-care in people living in rural areas. Thus, future qualitative studies may be
warranted to examine social circumstances that influence linkage to care among rural
PWID.
Because transportation was named a barrier to HCV treatment among urbandwelling PWID,10 we expected transportation to be a significant barrier. Rural areas may
have fewer if any modes of public transportation and residents usually have with limited
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access to reliable vehicles and/or gas money. However, transportation issues were not a
significant predictor of seeking HCV care in our study, although it did approach
significance and was self-reported as a reason for not seeking care by a few participants.
It is possible that with a larger sample it would be a predictor for rural residents.
Cost or financial burden was only reported in one prior study as a barrier to
linkage to care.10 Cost and lack of insurance accounted for a large percentage of
participants who did not seek care in our study. Not surprising, this is most likely due to
prior studies being conducted in a country with universal healthcare versus a country with
a multi-payer healthcare system.5-8, 10-12 Hence, practitioners should make an effort to help
PWID navigate the costs associated with healthcare.
3.5.1 Limitations
This study is among the first to provide data about barriers to seeking HCV care
among rural inhabitants in the U.S, a country without universal healthcare. However, a
few limitations are noted. First, our study may be underpowered due to our small sample
size. Second, our study was a secondary data analysis and is therefore limited to the data
collected. Therefore, we were not able to determine if factors that were important in
existing literature such as fear of treatment side-effects and invasiveness, HCVknowledge, and being a/symptomatic are predictors of linkage to care in this population.
In addition, we were not able to assess any provider-level barriers. It is possible that
variables not measured in our study are important predictors of linkage-to-care in this
population. Third, participants were asked to take part in a very lengthy survey. Longer
web-based surveys are associated with lower completion rates.13 Moreover, answers to
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questions towards the end of the survey are answered at a faster rate and in a more
uniform manner which brings to question the quality of responses.13
Fourth, participants were required to have functional literacy and basic computer skills to
complete the required online survey. It is reported that an estimated 30% of the
Appalachian population are functionally illterate14 and internet access is limited.15
Caution should be used in extending these findings to those with limited literacy and/or
no internet access. Lastly, as with most behavioral studies, our variables were self-report
measures and subject to social desirability and recall-bias. To minimize socialdesirability, participants were made aware that their data would be kept confidential and
de-identified during the consenting process. In addition, surveys were self-administered
which has clearly demonstrated a reduction in social desirability bias.16

3.6

Conclusions
Our findings suggest that barriers and facilitators associated with linkage-to-care

of rural inhabitants with limited access to health care are similar to barriers and
facilitators in urban areas and in countries with universal health care. Additional research
is needed to confirm these findings using a larger sample as well as provider-level and
system-level barriers to HCV care. Findings from these studies can then guide
interventions aimed at increasing linkage-to-care, treatment uptake, and ultimately
increasing cure rates in rural communities.
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Table 3.1 A comparison of sociodemographic variables of rural participants who did and
did not self-report seeking hepatitis C virus care
Total
Never sought
Sought HCV
P
sample
HCV care
care
n= 63
n= 36
n= 25
Gender
0.17
Male

40 (63.5)

27 (67.5)

13 (32.5)

Female

23 (36.5)

11 (50)

12 (50)

62 (98.4)

37 (97.3)

25 (100)

1 (1.6)

1 (2.6)

0 (0)

Race*
Caucasian
African American
Education

0.94

Less than high school

21 (32.8)

12 (57.1)

9 (42.9)

High school/GED

26 (42.9)

16 (42.1)

10 (40)

Some college or
technical school

15 (323.8)

8 (21.1)

6 (24)

Employment

0.48

Employed

21 (33.3)

13 (32.2)

8 (32)

Unemployed

42 (66.7)

25 (65.8)

17 (68)

*Chi square not run due to small sample size. Values are n (%).
GED = General Education Development. HCV = Hepatitis C Virus.
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Table 3.2 Self-reported reasons for not seeking HCV care among rural residents who
inject drugs
Reasons
Number of participants*
n (%)
Could not afford it

9 (25)

Did not know where to go

8 (22.2)

Did not have insurance coverage

7 (19.4)

Not worried about HCV

5 (13.9)

Recent drug use

4 (11.1)

Did not know treatment was available

4 (11.1)

Worried about side effects

3 (8.3)

Did not have transportation

3 8.3)

Worried MD would not treat them

2 (5.6)

Incarcerated

1 (2.8)

Worried it would be a waste of time

1 (2.8)

Recently diagnosed

1 (2.8)

HCV = Hepatitis C Virus; MD = Medical Doctor *options are not mutually exclusive.
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Table 3.3 Predictors of Seeking Hepatitis C Virus Care among Rural Residelnts Who Inject
Drugs (n= 63)
Odds Ratio (95% CI)
P-value
Primary caregiver of a child

0.803 (0.167-3.854)

0.784

No recent injection drug use

0.121 (0.015-0.994)

0.049

Had recent suboxone or
methadone use

5.002 (0.748-33.446)

0.097

Had transportation issues

3.169 (0.839-11.974)

0.089

Had recent criminal issues

0.763 (0.229-2.54)

0.659

Was recently homelessness

0.934 (0.261-3.346)

0.916
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Figure 3.1 Progression Through the Hepatitis C Virus Care Cascade among Ruraldwelling People Who Inject Drugs

Reported history of
injection drug use
46.2% (115/249)

Screened for HCV:
83.4% (96/115)

Tested positive for
HCV antibodies
65.6% (63/96)

Sought HCV care:
60.3% (38/63)

HCV treated: 7.9%
(5/63)

HCV cured: 3.1%
(2/63)
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CHAPTER 4. PREDICTORS OF PRIMARY CARE USE AMONG FEMALE
INMATES WHO INJECT DRUGS LIVING IN RURAL APPALACHIA
Abstract
Hepatitis C virus (HCV) infection is a growing epidemic with highest prevalence
among people who inject drugs (PWID) especially those in rural Appalachia and inmates.
To receive HCV treatment, one must be screened and referred to a HCV specialist.
Primary care providers (PCPs) are ideally situated to provide these services. However,
PWID are at an increased risk for contracting HCV but are less likely to access PCPs.
Factors associated with accessing a PCP include being female and employed while low
socioeconomic status, daily injection drug use, illegal income, and chronic homelessness
have been identified as barriers. Few studies have evaluated vulnerable subpopulations of
PWID such as those living in rural communities or inmates PURPOSE: To identify
predictors of PCP use among incarcerated female PWID living in rural Appalachia.
METHODS: This was a secondary analysis of data from 302 incarcerated female PWID
from a larger randomized control trial. Multivariate logistic regression was used to
determine predictors of primary care use. RESULTS: The majority (55%) of the sample
had less than a high school education, were single (35.7%) and were unemployed (74.5%)
with an average age of 32 (+/-7.92) years. Age (OR 1.05, CI 1.01-1.09, p = 0.01) and
reporting a lack of insurance as a barrier to seeking healthcare (OR 1.95, CI 1.12-3.4, p =
0.02) were significant predictors of PCP use. CONCLUSIONS: Knowing that younger,
rural-dwelling female inmates with a history of injecting drugs are more likely to not use
PCP services- clinicians should use opportunities such as emergency departments, jails,
prisons, urgent treatment centers, and addiction clinics to screen and refer to specialist.
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4.1

Introduction
People who inject drugs (PWID) are at the highest risk for contracting HCV, a

blood-borne viral infection affecting 2.4 million people in the United states.1 As the
opioid crisis continues to grow, so do acute cases of hepatitis C virus (HCV) infection. In
fact, acute cases of HCV infection have been on the rise since 2004, coinciding with the
opioid epidemic and increasing rates of injection drug use.2 A recent analysis of several
national data bases indicates a steady rise in HCV cases across the nation, with the largest
seen east of the Mississippi River.3 This is even more pronounced in Appalachian states
(Tennessee, West Virginia, Virginia, Kentucky) where the incidence of acute HCV
infections increased by 45% from 2006-2012 among people less than 30 years old with
approximately 75% reporting injection drug use as their primary risk factor.3
Naturally, inmates are another at-risk group since a history of drug use is common
among inmates.23 In fact, incarcerated persons have 2-10 times higher prevalence of HCV
infections than the general population with an estimated 29% of incarcerated persons in
North America testing positive for HCV antibodies (indicating prior exposure to the
virus). 4 This is more pronounced among female inmates. Forty to fifty percent of female
inmates have chronic HCV infections; that is a 20 times higher rate of infection than the
general population.6 In addition, a staggering 33% of Americans infected with HCV will
enter into a correctional facility each year.28
Rates of infection are highest among rural female inmates with a history of
injecting drugs however cure rates remain low. This low cure rate is owed to a not being
screened/diagnosed and/or linked to care. 7 Primary care providers (PCP) are ideally
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situated to facilitate progression through the HCV care cascade. In fact, visiting a PCP is
associated with lower risk of HCV infection, increased likelihood of being screened,
increased awareness of HCV status, and increased likelihood of being linked to a
specialist.8-10 However, PWID, often underutilize PCP services.9 This is even more
pronounced in female inmates.5, 11An estimated one third of PWID reported visiting a
PCP within the last month.13-14 However, only one third of female inmates reported
seeing a PCP when acutely ill in the last year11 and only half who reported a chronic
illness saw a PCP in the 12 months prior to incarceration.12
Upon release many inmates return to a community with limited access to
healthcare (i.e. rural areas) and endure disruptions in treatment for mental health, medical
conditions, medications, and substance use disorders.24-27 Moreover, most inmates lack
health insurance upon release and if they had Medicaid benefits prior to incarceration,
those benefits have since been terminated leaving them in a vulnerable position.28
Therefore, rural female inmates represent a vulnerable, unreached group of PWID that
are at an increased risk for contracting HCV but unlikely to receive the appropriate
medical care and needed follow-through.
4.1.1 Primary Care Utilization among People Who Inject Drugs
Factors associated with a significantly higher likelihood of seeing a PCP within
the last month include: being female, employed, living with children, and recent contact
with social/welfare worker.14 Low socioeconomic status (monthly income less than
$400), daily injection drug use, illegal or semi-illegal income, and chronic homelessness
were associated with a lower likelihood of a recent PCP visit. 13-14
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PWID self- reported barriers to healthcare access include the burden of
appointments, lack of transportation, negative staff attitudes, and fear of receiving bad
news pertaining to their health.15 The impact of these barriers on accessing healthcare
appeared to be contingent on the attitudes of healthcare professionals, the circumstances
and needs of the PWID, the availability of alternative services, and the frequency of
needed care.15 Self-reported facilitators of healthcare utilization included trust in
physician, presence of health insurance, supportive relationships (e.g., familial), personal
circumstances/life events (e.g., becoming a parent), and the individual’s state of mind
(i.e., feeling motivated and positive).16-17
4.1.2 Anderson’s Behavioral Model of Health Services Use
Utilization of healthcare services is a complex interaction between individual,
environmental, and healthcare characteristics.18 Andersen developed the Behavioral
Model of Health Services Use (Figure 1) to explain this dynamic relationship.18 Andersen
proposed use of health services was a result of the interaction of predisposing factors,
potential enabling resources, and need or current level of illness.18 Predisposing factors
are comprised of demographics, social structure, and health beliefs.18 Demographics
include age, gender, and ethnicity whereas social structure includes educational level and
social class.18 Health beliefs are values, attitudes, or knowledge about health and health
services that may influence perceived need and use of health services.18 Enabling
resources, include personal, family, and community factors that facilitate the use of
health services such as income, health insurance status, and distance traveled.18 Need is
divided into perceived and evaluated where perceived need is one’s perception of his/her
own general health and functional state.18 Evaluated need is defined as professional
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assessment of one’s health status and the need for health care.18 Anderson’s model will
serve as the framework for this study.

4.2

Specific Aims
The specific aims were (1) to identify independent predictors of primary care use

(defined as having one healthcare facility usually attended prior to incarceration) from
predisposing factors (age, marital status, highest educational achievement, employment
status, worried about health in the past 12 months, perceived chance of getting HCV),
potential enabling factors (insurance coverage, total family 6 month income, too far to
go), and healthcare needs (health problems interfered with responsibilities, perceived
health); and (2) to determine whether primary care use is a predictor of positive HCV
antibody.

4.3

Methods
4.3.1 Design, Setting, and Participants
This was a secondary analysis of data from 384 participants in a randomized

clinical trial (NIH/NIDA 1R01-DA033866) to determine changes in high-risk behaviors
and health service utilization in response to traditional education versus motivational
interviewing. Data were collected from drug-using rural women from county jails who
were at high-risk for HIV and HCV. Inclusion criteria were: 1) National Institute on Drug
Abuse-modified Alcohol, Smoking and Substance Involvement Screening Test score of
four or greater (moderate to high drug use); 2) engagement in at least one sex risk
behavior in the past three months; 3) willingness to participate in brief intervention
sessions; 4) incarceration period between two weeks to three months; and 5) reported a
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prior history of injection drug use. Participants were excluded if they had a documented
mental illness or cognitive impairment.
4.3.2 Procedures
The parent study was approved by the Institutional Review Board and a Federal
Certificate of Confidentiality was obtained. Participants were enrolled in the larger study
trial and completed baseline interviews before being randomly assigned to one of two
conditions- HIV Education or Motivation Interviewing. Only baseline data were used for
this secondary analysis.
4.3.3 Measures
The primary outcome for this secondary analysis was PCP use. PCP use falls under
the umbrella of healthcare utilization- defined as the description of the use of services by
persons for prevention, maintenance or cure of health problems, and for overall wellbeing.19 Self-report measures of health care use (e.g. hospital and office visits) have
moderate to high agreement with administrative health care claims, especially pertaining
to office visits.20 Agreement between the two are highest when evaluated via internetsurveys.21 We therefore, operationally defined primary care use as participants’ selfreport of having a clinic/health center/doctor’s office/other facility that they usually
attended prior to incarceration.
4.3.3.1 Predisposing Factors
The predictor variables for this secondary analysis were based on Andersen’s Model
of Health Care Use and on review of the literature (Figures 1 and 2).18 Age (in years) was
the only demographic variable measured. All participants were Caucasian females;
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therefore, ethnicity and gender were not included. Social structure was operationally
defined as highest level of education (less than high school, high school, or some higher
education) and employment status (employed/unemployed). Health beliefs were
measured as being worried about health in the past 12 months (yes) and perceived chance
of getting HCV (less than 50%).
4.3.3.2 Enabling Factors
For this analysis, we used income, health insurance status, and travel distance as
enabling factors. Income was measured based on total income 6 months prior to
incarceration in U.S dollars, health insurance status was measured as “was no health
insurance a barrier to seeking needed healthcare services?” (yes), and travel distance was
measured as “was it too far to go a barrier to seeking needed healthcare services?” (yes).
4.3.3.3 Perceived Need
Perceived need was measured as “have health problems kept you from meeting
responsibilities at work, school or home?” (yes) and perceived health in last 12 months
(fair to poor).
4.3.3.4 Hepatitis C Virus Antibody Testing
Hepatitis C Virus antibody testing was performed using OraQUICK ADVANCE®
Rapid HCV Antibody Test kits, which have demonstrated sensitivity (95.5-100%) and
specificity (99.2-100%) similar to current laboratory-based EIA (gold standard).21
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4.3.4 Statistical Analyses
Data were analyzed using SPSS 25.0 with an alpha set at 0.05. Independent t tests
were calculated for continuous variables and Chi square for categorical variables to
compare those who reported primary care use with those who did not. Multivariate logistic
regression was run to address Specific Aim 1 in which the following independent
variables were forced entered in one step: (1) age, (2) highest level of education, (3)
employment status, (4) being worried about one’s health, (5) perceived chance of getting
HCV, (6) six-month income, (7) insurance status, (8) travel distance, (9) perceived need,
(10) perceived health. Univariate logistic regression was run to address Specific Aim 2;
determine whether HCV antibody status predicts being in the group that reported use of a
PCP prior to incarceration.
No assumptions were violated in either logistic regression model. The assumption
of a linear relationship between age and income and the logit transformation of the
dependent variable (having one healthcare facility that they usually visited) was tested and
found to not be violated. There was no multicollinearity or significant outliers/influential
points.
4.3.5 Results
Our analysis included a total of 302 PWID (Table 1). All participants were
Caucasian females. The majority (55%) had not graduated high school, were single
(35.7%), and were unemployed (74.5%). On average, our sample was approximately 32(+/7.4) years of age and had a total average income of $9,222.05 (+/- 20,855.41) six months
prior to incarceration. A majority (58%) of our sample reported using primary care services
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prior to incarceration. Those who reported PCP use were significantly older (33 +/- 7.9 vs.
30 +/-6.4 years, p = 0.01).
Our multivariate logistic regression model is presented in Table 2. The model was
significant (p = 0.01). Age was the only predisposing factor to predict primary care use.
Participants were 5% more likely to use healthcare for each additional year of age (OR
1.05, CI 1.01-1.09, p = 0.01). Income as a continuous variable was highly variable and
therefore not included in the regression model. Interestingly, participants who reported that
a lack of insurance was not a barrier to healthcare were 95% more likely to engage in
primary care services (OR 1.95, CI 1.12-3.4, p = 0.02). The remaining enabling factors
were not predictors of primary care use. Reporting health problems that interfered with
responsibilities was a significant need factor. Those who reported having health problems
that interfered with other responsibilities in the last 12 months were about 40% more likely
to have engaged in primary care services (OR 0.60, CI 0.33-1.07, p = 0.08).
Results from our univariate logistic regression model are presented in Table 3.
HCV antibody status (positive versus negative) was not a predictor of primary care use.

4.4

Discussion
In alignment with Anderson’s Model, we found that age and lack of insurance

were barriers to PCP use. A lack of insurance as a barrier to accessing needed healthcare
was the single most important predictor of not seeing a PCP. This is alarming in a group
of women who will upon release face limited access to healthcare services, lack of or
suspension of health insurance and disruption in continuity of healthcare.24-28
Inconsistent with his model, employment status, marital status, chance of getting
HCV, being worried about one’s health, health issues that interfere with one’s
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responsibilities, distance traveled, and perceived health were not predictors of primary
care use. One reason for this difference, could be that this vulnerable population faces
numerous barriers to care and this model did not account for the additive effects of
multiple barriers.
Contrary to prior studies among PWID13-14, employment status was not a
predictor of primary care use. This difference may be due to the majority of our sample
being unemployed and therefore employed females were underrepresented in our sample.
In prior studies, transportation issues were a barrier to healthcare utilization15
however, we found that distance traveled was not a significant barrier. This could be
related to how we measured this barrier. We operationalized transportation issues as, ‘is
distance a barrier to healthcare use”. Perhaps lack of a reliable vehicle or gas money
rather than distanced traveled contributed to difficulty with transportation. Or perhaps,
they were incarcerated at the time of needed healthcare services and transportation alone
was not the hindering factor. Moreover, asking our participants to be introspective and
determine if distance is a barrier may produce different results as opposed to evaluating
associations between distance traveled and PCP use.
4.4.1 Limitations
Our study has some limitations that warrant consideration. First, we used an
indirect measure of primary care use rather than administrative healthcare claims. There
is considerable data that supports the reliability of self-report measures of healthcare use.
However, there are numerous ways to ask patients about use of primary care services.
Depending on how this is operationalized, it could render different findings. Because this
was a secondary analysis, we were not able to examine an exhaustive list of
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barriers/facilitators. Therefore, it is possible that other factors are influential in PCP use.
While our sample size of 302, was acceptable, our sample size restricted the number of
predictor variables we could use in our model. Last, are data were primarily self-report
measures. Self-report measures are vulnerable to social desirability bias in which the
participants may answer in the most favorable way. Self-report measures are also
susceptible to recall bias.

4.5

Conclusions
Our findings suggest only two predictors of PCP use among this vulnerable

population. Additional research is needed to find other predictors of PCP use among
rural-dwelling female inmates with a history of injecting drugs. Special attention should
be given to examining provider level barriers as well as the additive effects of multiple
potential barriers in this population.
In the meantime, our findings can be applied at the clinical and policy level.
PWID can be very transient (frequently relocating, changing phone numbers, etc.) but
while incarcerated they remain in a fixed location and therefore are an ideal target for
interventions. Specifically, jail staff could offer information about Medicaid eligibility
after release. This responsibility extends beyond jail staff to healthcare personnel who
should provide at-risk individuals (i.e. those who are underinsured or uninsured and
young PWID) with information on local facilities that offer sliding-scale/income-based
payment plans. Clinicians should also use alternative contacts such as emergency
departments, jails, prisons, urgent treatment centers, and addiction clinics to screen for
HCV and refer to specialists. On a policy level, greater access to affordable insurance is a
clear necessity to increase PCP use among female PWID inmates.
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Table 4.1 Comparison of socio-demographic variables of people who inject drugs and
used primary care services with those who did not
Total (n=302)
No regular
Regular
P-Value
healthcare
healthcare
facility, n=127 facility, n=175
Age (Years)

31.6+/-7.5

29.9+/-6.4

32.9+/-7.9

0.01

Total income
in 6 months
before
incarceration

9222 ± 20855

8268 ± 17026

9908 ± 23249

0.48

Highest level
of education

0.37

Less than high
school

154(50.1)

70(55)

84(48)

Completed
high school

88(29.14)

36(28.3)

52(29.7)

Some higher
education

60(19.9)

21(16.5)

39(22.3)

Marital Status:

0.01

Married

95(31.5)

37(29.1)

58(33.1)

Single

108(35.8)

57(44.9)

51(29.2)

Separated,
widowed,
divorced

99(32.7)

33(25.6)

66(37.8)

Employment
Status:

0.32

Employed

63(20.9)

23(18.1)

40(22.9)

Unemployed

239(79.1)

104(81.9)

135(77.1)
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Table 4.2 Predictors of Primary Care use among Female Inmates with a History of Injecting
Drugs Living in Rural Appalachia
Odds Ratio
95% Confidence
P value
Intervals
Omnibus model Χ2 = 36.998, df 13, p <0.001
Age (Years)

1.05

1.01-1.09

0.01

Employment status 6 months
Unemployed
Employed

Reference
1.8

0.95-3.41

0.07

Highest level of education
Some higher
Education

Reference

High School

0.62

0.31-1.22

0.16

Less than high
School

0.81

0.39-1.67

0.56

Marital status
Separated,

Reference

divorced,
widowed
Not Married

0.99

0.52-1.87

0.97

Married

0.59

0.32-1.11

0.11

Perceived chances of getting Hepatitis C
High (75-100%)
Small to
Moderate

Reference
0.8

0.47-1.35

0.40

(0- 50%)
Worried about health/behaviors during past 12 months
Yes
No

Reference
0.636

0.35-1.17

54

0.15

Table 4.2 (Continued)
No insurance coverage a barrier seeking needed health care services
Yes
No

Reference
1.95

1.12-3.4

0.02

Distance a barrier to seeking needed health care services
Yes
No

Reference
1.09

0.61-1.97

0.77

Had health problems that prevented meeting responsibilities at work, school or home
during past 12 months
Yes
No

Reference
0.596

0.33-1.07

0.08

Perceived health in last 12 months
Good to Excellent
Poor to Fair

Reference
0.64

0.35-1.17

55

0.15

Table 4.3 Hepatitis C antibody status as a predictor of primary care use (n= 277)
Odds ratio
95% confidence
P value
intervals
Hepatitis C antibody status
Positive

Reference

Negative

1.320

0.791-2.203

56

0.288

Figure 4.1 Andersen’s Behavior Model of Health Services Use
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Figure 4.2 Predictor variables included in logistic regression model
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CHAPTER 5. CONCLUSIONS
5.1

Background and Purpose
Untreated hepatitis C can have grave consequences.1 Fortunately, HCV can be

cured with direct acting antiviral therapy.2 PWID and inmates are among those with the
highest incidence of HCV but cure rates in these populations remains low.3-6 Inadequate
screening and linkage to care remain among the largest impediments to successful
treatment.2
The purpose of this dissertation was to develop a broader understanding of the
barriers and facilitators to healthcare utilization among rural-dwelling People Who Inject
Drugs (PWID) at the primary care level, where screening for hepatitis C virus (HCV)
may take place and at the specialist level (linkage to care). The following three
manuscripts addressed important gaps in knowledge: (1) a review of the literature to
describe the state of science on linkage to care among PWID, (2) a cross-sectional study
to determine whether predictors of linkage to care identified in urban-dwelling PWID
from countries with universal healthcare predicted seeking HCV care among PWID
living in rural Appalachia, and (3) a cross-sectional study to determine predictors of
primary care provider (PCP) use among female inmates living in rural Appalachia with a
history of injecting drugs.
This chapter will summarize the findings of this dissertation with the intention of
advancing the state of science on healthcare use (primary care and specialist care) among
rural-dwelling PWID. This chapter will also provide recommendations for clinical
applications and future research.

59

5.2

Summary of Findings
Chapter Two is a review of the literature on the current state of science on linkage

to HCV care among PWID. We reviewed a total of seven studies, two of which were
qualitative, four were quantitative and one was mixed methods. Four studies were
conducted in Australia, two in Ireland and one in Greece. In all seven studies, patients
were recruited from addiction-based clinics or community service facilities. Only two
studies were conducted after direct acting antiviral therapy became standard of care.
Barriers to linkage-to-care at the patient-level included: ongoing substance use, limited
knowledge about HCV, competing priorities, and being asymptomatic. Distance traveled,
lack of transportation, and early appointment times were reported as system-level
barriers. Facilitators at the provider-level included elevated liver enzymes, diagnosis of
cirrhosis, and a trusting patient-provider relationship.
Chapter Three is a cross-sectional study in which we examine predictors of
seeking HCV care among rural-dwelling PWID. Our final analysis included sixty-three
HCV positive PWID. Inconsistent with prior studies,7-9 recent injection drug use was a
(and the only) predictor of seeking HCV care. Self-reported use of Opioid Substitution
Therapy in the last six months and transportation issues seemed to be important but were
not statistically significant. Inconsistent with existing literature12-13 self-report of criminal
issues, homelessness, and being the primary caregiver of a child in the last six months
were not predictors of seeking HCV care. The following were the most commonly selfreported barriers provided by HCV positive PWID who did not seek care: could not
afford care (n= 9), did not know where to go (n= 8), no insurance coverage (n = 7), not
worried about HCV (n = 5), did not know treatment was available (n = 4), recent or
ongoing drug use (n=4), transportation problems (n = 3), and being worried about
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treatment side effects (n =3) and are consistent with prior findings.10-12 Our findings
suggest some differences between barriers/facilitators to seeking HCV care among rural
and urban dwelling PWID.
Chapter Four is a cross-sectional study to determine predictors of PCP use among
rural-dwelling inmates with a history of injecting drugs. Our analysis included a total of
302 participants. Age and no insurance issues were significant predictors of primary care
use. Participants were 5% more likely to use healthcare per each additional year of age and
participants who reported a lack of insurance was not a barrier to healthcare were 95%
more likely to engage in primary care services. Our results suggest that there are
differences between rural-dwelling female inmates with a history of injecting drugs
compared to their non-incarcerated urban counterparts.

5.3

Impact of Dissertation on the State of Science
This dissertation has advanced the state of science on the predictors of primary care

use and linkage to care among vulnerable populations (rural-dwelling, female inmates) by
(1) identifying gaps in the literature, (2) describing predictors and self-reported barriers to
seeking HCV care among rural-dwelling PWID after the advent of direct acting antiviral
therapy, and (3) determining predictors of PCP use among rural-dwelling female inmates
with a history of injecting drugs.
Chapter Two revealed several gaps in the literature on predictors of linkage to
care. First, there is an overall lack of knowledge about barriers and facilitators of linkage
to care among PWID with only seven studies meeting inclusion criteria. Nearly 40% of
the reviewed studies were qualitative data and only one study examined longitudinal
data8 over 2-5 years. Second, findings from existing literature lack generalizability.
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Researchers in only one study recruited participants from rural areas 11; all others
recruited participants from urban cities and countries with universal healthcare. In
addition, participants for all studies were recruited from community health centers,
needle exchange programs or addiction treatment facilities, often with onsite HCV
treatment available. This demonstrates a lack of real-world data. Third, only two studies 9,
12

were conducted after direct-acting antiviral (DAA) therapy became standard of care

and therefore, it remains unclear if fear of side effects is still important. Lastly, linkage to
care was operationally defined differently in each study and likely attributes to
inconsistent findings in the literature.
Chapter Three broadened our understanding of barriers and facilitators to seeking
HCV care among PWID by providing insights on barriers/facilitators faced by rural
PWID. Specifically, our findings illuminate key differences between urban PWID from
countries with universal healthcare in a Pre-DAA era and rural PWID from countries
with a multi-payer healthcare system in a post-DAA era. We found three key differences.
First, our sample of recent injection drug users were more likely to be linked to care.
Second, consistent with our expectations, fear of side-effects related to HCV treatment
are much less relevant in the post-DAA era. Lastly, our findings suggest that cost
associated with healthcare and lack of insurance are very important barriers for rural
PWID in countries without universal healthcare.
Chapter Four represents to our knowledge, the only study to examine predictors
of PCP use among rural, female inmates with a history of injecting drugs. The results
illustrate the need to improve insurance access to this vulnerable population. In addition,
we identified differences between rural and urban dwelling PWID.
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5.4

Recommendations for Clinical Practice and Research
We conducted one study to address one of the gaps identified in Chapter 2, but

additional research is needed to confirm these findings and expand the existing
knowledge base. Specifically, longitudinal data and more real-world data are needed that
focuse on vulnerable populations with high rates of infections such as those residing in
rural areas, jails, prisons, etc. Ideally, a large study should be conducted following rural
PWID from time of diagnosis and over several years to determine predictors of linkage to
care. More current research is also needed in the new DAA treatment era to determine if
fear of side effects or concerns about the ineffectiveness of treatment is still relevant.
Lastly, consistency should be used in how linkage to care is defined. In the interim,
caution should be used in generalizing these findings to real-world populations.
Findings from Chapter Three suggest that while there are similarities in barriers
and facilitators associated with to linkage-to-care in rural inhabitants, there are also some
key differences. Additional research is needed to confirm these differences using a larger
sample size of rural PWID. In addition, future studies should attempt to obtain more
objective predictor variables as opposed to relying exclusively on self-report measures.
Future research is also needed to determine system-level and provider-level barriers
among vulnerable populations such as PWID.
In Chapter Four, we found that younger age and no insurance were barriers to
PCP use among female inmates with a history of injection drugs. Knowing this,
clinicians should target this vulnerable group and seek out opportunities to screen and
refer to specialist. For example, when clinicians encounter young and/or uninsured PWID
in an emergency department, jail, prison, urgent treatment center, and/or addiction clinic,
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they should offer information about free screening sites or treatment facilities that offer
income-based payment plans.
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